

1 **Small-form-factor LED-based light application surface for indocyanine green-mediated**  
2 **antibacterial photothermal therapy**

3  
4 Sakari Nikinmaa<sup>1</sup>, Niina Moilanen<sup>2</sup>, Timo Sorsa<sup>2,3</sup>, Juha Rantala<sup>1</sup>, Heikki Alapulli<sup>2</sup>,  
5 Anja Kotiranta<sup>2</sup>, Petri Auvinen<sup>4</sup>, Esko Kankuri<sup>5</sup>, Jukka Meurman<sup>2</sup> and Tommi Pätilä<sup>6,\*</sup>

6  
7 <sup>1</sup> Department of Neuroscience and Biomedical Engineering, Aalto University, Espoo, Finland

8 <sup>2</sup> Faculty of Medicine, Department of Oral and Maxillofacial Diseases, University of Helsinki  
9 and Helsinki University Hospital, Helsinki, Finland

10 <sup>3</sup> Department of Oral Diseases, Karolinska Institutet, Huddinge, Sweden

11 <sup>4</sup> Institute of Biotechnology, University of Helsinki, Helsinki, Finland

12 <sup>5</sup> Faculty of Medicine, Department of Pharmacology, University of Helsinki, Helsinki,  
13 Finland

14 <sup>6</sup> Department of Congenital Heart Surgery and Organ Transplantation, New Children's  
15 Hospital, University of Helsinki, Helsinki, Finland

16  
17 Short Title: Plaque reduction by small-form-factor aPTT applicator

18  
19 \* Author for correspondence:

20 Tommi Pätilä, MD, PhD

21 Department of Pediatric Heart Surgery and Organ Transplantation

22 New Children's Hospital, Helsinki University, Stenbäckinkatu 9 00029-HUS

23 Tel: +358 50 427 2291, Fax: +358 94 717 4479

24 Email: tommy.patila@hus.fi

25 Keywords: dental plaque, gingivitis, antibacterial photothermal therapy

26  
27 **ABSTRACT**

28 We present here a small-form-factor LED-based antimicrobial photothermal therapy  
29 (aPTT) applicator surface, and its clinical feasibility as well as efficacy for administration of  
30 indocyanine green (ICG)-assisted aPTT to the dental plaque.

31 Fifteen healthy adults were assigned to this four-day randomized study. After rinsing  
32 with ICG, 100J/cm<sup>2</sup> of 810 nm light was applied to the aPTT-treatment area. Plaque area and  
33 gingival crevicular fluid (GCF) matrix metalloproteinase-8 (MMP-8) were measured, and  
34 plaque bacteriomes before and after the study were analyzed using 16S rRNA sequencing.

35 aPTT administration was performed successfully and plaque-specifically with the  
36 applicator surface. Total plaque area and endpoint MMP-8 levels were reduced on the aPTT-  
37 treatment side. aPTT reduced *Streptococcus*, *Acinetobacteria*, *Capnocytophaga*, and *Rothia*  
38 bacteria species in plaques. The applicator surface is feasible for aPTT self-administration,  
39 targets therapy to dental plaque, reduces plaque forming bacteria and exerts anti-inflammatory  
40 and -proteolytic effects.

41

## 42 INTRODUCTION

43 Dental diseases affect a staggering 3.5 billion people globally.<sup>[1,2]</sup> Dental caries or tooth  
44 decay is the most common worldwide health condition, while gingivitis, gum inflammation,  
45 affects 50-90% of adults.<sup>[1,2]</sup> If untreated, gingivitis can lead to periodontitis, a more severe  
46 inflammation causing irreversible oral tissue destruction and bone resorption around the teeth.  
47 Severe periodontitis, the major cause for tooth loss,<sup>[3-5]</sup> has a prevalence of 5-15% in most  
48 populations.<sup>[1,2]</sup> Importantly, poor oral hygiene and oral microbial dysbiosis are associated  
49 with the development or worsening of the course of several systemic diseases, thus adversely  
50 affecting the entire body.<sup>[5]</sup>

51 Antimicrobial photothermal therapy (aPTT) uses light emission to excite photosensitizer  
52 molecules. The resulting release of heat energy, and to a lesser degree reactive oxygen species  
53 (ROS), destroy bacteria, fungi and viruses.<sup>[6,7]</sup> Phototherapy, in general, is used in medicine to  
54 treat a wide range of medical conditions, including acne, psoriasis, and other skin conditions  
55 as well as different types of cancer.<sup>[8]</sup>

56 Indocyanine green (ICG) is a US Food and Drug Administration-approved dye for  
57 medical purposes. ICG is primarily employed in diagnostic approaches, such as assessment of  
58 hepatic function and perfusion-related analysis of tissues, due to its non-toxic nature and fast  
59 metabolism.<sup>[9]</sup> Recently, owing to its absorption peak close to the 810nm wavelength of  
60 dental caries removal lasers, ICG has arisen as a promising tool in dentistry. Upon excitation,  
61 ICG transforms approximately 88-85% of the absorbed energy to heat while less than 15% is  
62 released as singlet oxygen.<sup>[10]</sup> ICG-mediated aPTT has demonstrated therapeutic potential on  
63 dental pathogens and periodontitis.<sup>[10-16]</sup>

64 The administration of laser-assisted aPTT is limited to in-office use by dental  
65 professionals. In order to obtain most benefit, aPTT would require routine daily  
66 administrations, preferably as self-care.<sup>[17]</sup> Moreover, a small self-care instrument would  
67 facilitate oral health not only in high-income countries but also in low- and middle-income  
68 countries in which access to preventive oral healthcare and treatments can be limited.<sup>[18]</sup>

69 We present here an LED-based light application surface designed for self-managed  
70 aPTT administration (**Figure 1A**), and report its feasibility and efficacy in a randomized,  
71 split-mouth treatment-control clinical study on 15 healthy volunteers. We demonstrate the  
72 applicator surface's clinical feasibility as well as efficacy to decrease plaque formation,  
73 reduce the levels of gingivitis- and periodontitis-associated matrix metalloproteinase-8  
74 (MMP-8) and reduce the number of cariogenic streptococci in dental plaque. Our results

- 75 demonstrate the feasibility of the small-scale material design for self- or home-application and  
76 provide the first evidence to support its efficacy to reduce the amount of dental plaque.

## 77 MATERIALS AND METHODS

78 The study was approved by the ethics committee of the Hospital District of Helsinki and  
79 Uusimaa (HUS/827/2018) and was conducted in accordance with the ethical principles of the  
80 Declaration of Helsinki. All participants provided written informed consent before enrolment.  
81 The study is registered in the ISRCTN registry ([www.isrctn.com](http://www.isrctn.com)) under the trial number  
82 ISRCTN36318197. All variables were analyzed blinded to the treatment allocation.

83

84 **Study design** - This randomized, split-mouth study included 15 healthy volunteers. **Figure**  
85 **1B** presents the study design. aPTT was administered for a total of four times on four  
86 consecutive days using the small-form-factor LED-based light applicator surface (**Figure 1A**)  
87 after spurring the ICG photoactive substance. Inclusion criteria included good general health,  
88 age 18 to 65, and ability to refrain from brushing one's teeth throughout the study period.  
89 Exclusion criteria were diabetes, medications that may affect the immune response or saliva  
90 secretion, malignancy, pregnancy, dental implants or prosthesis, fixed orthodontic appliances,  
91 or active or chronic oral infection. Medications that could affect the oral microbiome, such as  
92 antibiotics, chlorhexidine or other antimicrobial mouthwashes, were not permitted during the  
93 study.

94 Two days before the study, a meticulous professional cleaning was performed on  
95 maxillary first premolars on both sides. The treatment side was randomized by coin flip, and  
96 the contralateral side served as the control. Study subjects were not allowed to brush or  
97 otherwise clean their teeth during the study period.

98

### 99 aPTT application

100 ICG powder (Verdye, Diagnostic Green GmbH, Aschheim, Germany) was dissolved in water  
101 at a weight/volume ratio of 7 mg/25 ml, and each subject spurted the solution for 60 s in their  
102 mouth prior to the light application. Near-infrared imaging was performed to ensure the  
103 localization of the ICG in the dental plaque (**Figure 1C, D**).

104 The small-form-factor LED-based light applicator surface included 16 0.5 W LEDs in a  
105 lollipop form, optimally located for producing an even light distribution (**Figure 1A**) to the  
106 teeth's surface.

107 Light application time was determined by the target light dose of 100 J/cm<sup>2</sup>, and the  
108 treatment time was set accordingly for 8 minutes per session. Light intensity was decreased if  
109 the person under examination felt that the heat of the light applicator was too intense. In such  
110 case, the reduction in light intensity was adjusted by an increase in treatment time to regulate

111 the target dose. This adjustment was performed with a light power meter (Thorlabs PM 100D  
112 with S121C sensor head, Thorlabs Inc, Newton, NJ, USA).

113

#### 114 **Plaque analysis**

115 The premolar teeth were photographed daily on both sides of the maxilla using a  
116 ProDENT PD740 dental camera (Venoka USA Inc, Windermere, FL, USA) under near  
117 infrared and white light lighting conditions to assess ICG adherence to the dental plaque.  
118 Daily imaging using a SoproCare camera (Acteon Group Ltd, Norwich, England) was carried  
119 out to assess the development of plaque formation. The final plaque imaging was performed  
120 with the ProDENT PD740 camera after plaque staining with an erythrosine tablet according  
121 to the manufacturer's instructions. The amount of dental plaque surface area was measured  
122 from the images of both adjacent upper premolars using Photoshop CC software (Adobe Inc,  
123 San Jose, CA, USA). On each side, the amount of plaque was determined as the plaque area  
124 pixels divided by the total maxillary premolar teeth area pixels.

125

#### 126 **GCF collection and MMP-8 analysis**

127 GCF samples were collected from the first premolar teeth on each side of the maxilla.  
128 Collection of GCF and measurement of clinical parameters were performed prior to any  
129 treatment measures, daily before the treatment, and after the last treatment. A total of 72x2  
130 GCF samples were collected from the treatment and control sites. GCF sampling was  
131 performed by inserting a PerioPaper strip (Oraflow Inc, NY US) into the orifice of the  
132 gingival sulcus. Samples were collected at the buccal surface, with the insertion point only  
133 minorly changing with every sample. GCF sampling was done carefully and it did not remove  
134 any observable amount of supra gingival plaque Strips contaminated by blood were discarded.  
135 The samples were stored in small aliquot containers and kept at -20° C until analysis. MMP-8  
136 levels were determined by a time-resolved immunofluorescence assay (IFMA) as described  
137 previously.<sup>[19-22]</sup>

138

#### 139 **16S rRNA bacterial samples**

140 Plaque samples were obtained with Iso Taper Paper Points, size-20 (VDW GmbH,  
141 Munich, Germany), by scrubbing the plaque on the tooth enamel. In all the plaque samples,  
142 the plaque was intact at the gingival boundary. Each sample was taken from same site by  
143 horizontally placing the paper point above gumline of premolar teeth. The paper points were

144 placed into sterile, small-aliquot containers, and were immediately stored at -20°C until  
145 analysis.

146 16S rRNA sequencing was performed as described earlier.<sup>[23]</sup> The V3-V4 regions of the  
147 16S rRNA genes were amplified using universal bacterial primers and sequenced with an  
148 Illumina MiSeq sequencer (Illumina Inc., San Diego, CA, USA). Bioinformatic analysis,  
149 including operational taxonomic unit (OTU) clustering and taxonomy assignment were done  
150 using Mothur software.<sup>[24]</sup> The 16S rRNA sequences have been deposited to the Sequence  
151 Read Archive (SRA) of the National Center for Biotechnology Information (NCBI) under  
152 BioProject ID PRJNA661546.

153

#### 154 **Statistical analysis**

155 Statistical analyses were performed using GraphPad Prism 6.0 (GraphPad Software Inc.,  
156 San Diego, CA, USA). Unpaired comparisons between the groups were performed with the  
157 Mann-Whitney test. The paired rank-sum Wilcoxon test was used for the paired samples.  
158 Two-way Anova was used to compare the daily values of MMP-8 between groups.  
159 Comparisons of categorical variables were performed using Fisher's exact test. Data are  
160 presented as mean  $\pm$ SEM unless otherwise specified.

## 161 RESULTS

162 Thirteen subjects completed the entire study protocol. One dropout occurred two days  
163 into the study due to a non-related acute infection, and another four days into the study, just  
164 after the 16S sampling and just before the plaque imaging, due to a work-related emergency.

165

### 166 Dental plaque formation

167 All subjects were plaque-free at the beginning of the study period. ICG was  
168 demonstrated to attach selectively to the dental plaque (**Figure 1C**). Sopro chromatic  
169 mapping did not show any difference in the development speed of the plaque between the  
170 aPTT-treatment and control sides. At the end of the study, erythrosine-based plaque-enclosing  
171 imaging showed significantly less plaque on the aPTT-treated premolars than controls  
172 ( $35.1 \pm 4.8\%$  vs  $42.5 \pm 4.0\%$  of the surface area;  $p=0.016$ ; **Figure 2**).

173

### 174 Gingival crevicular fluid MMP-8 levels

175 At the beginning of the study, two days after meticulous professional cleaning GCF  
176 MMP-8 concentrations on both sides were similar. Evaluation of daily pre-treatment MMP-8  
177 concentrations throughout the study using an area under curve analysis demonstrated a trend  
178 for lower overall MMP-8 concentrations in the treated group (AUC  $256.7 \pm 99.7$ , 95%CI 61.2-  
179 452.1) as compared to the control side (AUC  $344.9 \pm 113.2$ , 95%CI 123.0-566.8). However,  
180 the GCF MMP-8 levels at the end of the study after aPTT administration demonstrated a  
181 significant reduction on the aPTT-treated side (**Figure 3A**).

182

### 183 Microbiome analysis and alpha diversity

184 Fourteen paired pre-treatment and posttreatment 16S samples were collected. One  
185 sample was disqualified due to low sample quality, because it showed significantly lower  
186 bacterial counts together with a significantly reduced amount of OTUs detected. The number  
187 of streptococcal species on the aPTT-treated side (median 7460, range 6734-23987) was  
188 significantly reduced as compared to the control side (median 12776, range 4959-38669,  
189  $p=0.0024$ ). Similarly, reduced numbers of *Rothia* species (median 13, range 3-908 vs. median  
190 82, range 3-2883,  $p=0.0032$ ), *Capnocytophaga* species (median 1050, range 11-4382 vs.  
191 median 1220, range 15-8599;  $p=0.0402$ ) and *Actinomyces* species (median 141, range 16-  
192 1833 vs. median 933, range 12-3608,  $p=0.0005$ ) were detected on the aPTT-treated vs control  
193 sides. Increases in the OTU-amounts of *Neisseria* [median 7211, range 201-22892 vs. median  
194 2169, range 122-11792,  $p = 0.0327$ ], *Haemophilus* species [median 7599, range 713-28727

195 vs. median 2935, range 524-27988,  $p=0.0479$ ), and *Leptotrichia* (median 307, range 1-5524  
196 vs. median 105, range 4-3431,  $p=0.0105$ ) were found on the aPTT-treated vs. the control side  
197 (**Figure 3B**).

## 198 **DISCUSSION**

199 We present here a surface assembly for self-administration of aPTT and demonstrate its  
200 feasibility and effectivity in a four-day clinical study. In addition to self-administration  
201 feasibility, our results demonstrated reduced dental plaque, reduced the levels of the gingivitis  
202 and periodontitis biomarker GCF MMP-8 as well as reduced amount of cariogenic and  
203 periodontitis-associated bacteria on the aPTT-treated side. Moreover, alpha diversity of the  
204 plaque microbiome was retained throughout the study period.

205 Plaque-selective binding of ICG photosensitizer occurred effectively after solution  
206 spurting suggesting a targeted effect on the plaque bacteria sensitive to aPTT.<sup>[25]</sup> Further  
207 targeting is achieved through localized ICG excitation by the LED-based light applicator  
208 surface. In contrast to the coherent and intense laser beam used in laser-based devices, the  
209 LED light sources produce scattered, wide-spreading light without hotspots. This reduces  
210 risks associated with laser light, such as eye damage and thermal injury to tissues.<sup>[26]</sup> An  
211 additional benefit of the LED-based surface is the improved total amount of light when  
212 compared to laser devices. Finally, the most enticing element of LED light is the ease of use  
213 and general safety, which are important for daily use at home.

214 In samples collected daily before aPTT administration, no significant overall differences  
215 in GCF MMP-8 were observed during the study period. However, when collected after the  
216 administration of aPTT at the end of the study, the levels of GCF MMP-8 were significantly  
217 lower on the treated side as compared to the control side not receiving aPTT. This result  
218 suggests that aPTT, as administered using ICG as the sensitizer and the small-scale LED-  
219 based light applicator surface, can help reduce gingivitis-associated local inflammation and  
220 provide additional therapeutic and putative preventive effects.

221 Greatest reduction of bacteria in dental plaque by aPTT was observed in streptococci  
222 indicating good potential in reduction of dental plaque cariogenicity. We found additional  
223 reduction in capnocytophaga, acinetobacteria, and rothia species. These low pathogenicity  
224 bacteria are generally associated with good health.<sup>[27,28]</sup> We found the neisseria species to be  
225 relatively increasing in the plaque on the treated side. Neisseria have been associated with  
226 healthy oral flora, with a correlation to having a younger age, having a lower body mass  
227 index, having fewer caries, and being a non-smoker.<sup>[29]</sup> Also, the haemophilus species were  
228 found to increase in the aPTT treated dental plaque. Haemophilus species have been shown in  
229 several studies to be endowed with healthy periodontal status,<sup>[30]</sup> and larger amounts of  
230 haemophilus counts have been found in shallower periodontal pockets.<sup>[31]</sup>

231            In conclusion, our results demonstrate the feasibility of the self-care-compatible small-  
232    scale aPTT surface assembly and provide the first evidence of its clinical effectivity.

**233 ACKNOWLEDGEMENTS**

234 We thank Nina Aspinen for help in dental photography, data collection, anonymization  
235 and analysis, and Saija Perovu for technical assistance and support. We thank the personnel  
236 of DNA sequencing and genomics laboratory for making the 16S analysis work.

**237 DISCLOSURE STATEMENT**

238 T.P., S.N. and J.R. are co-founders in Koite Health Oy, a start-up company providing  
239 antibacterial photothermal solutions for dentistry.

**240 FUNDING SOURCES**

241 This research is part of a TUTL-project funded by Aalto University and Tekes  
242 (4364/31/2016).

**243 AUTHOR CONTRIBUTIONS**


244 T.P., S.N., J.R., A.K., N.M., J.M., E.K. and A.H. contributed to the design of the work.  
245 TS was responsible for the MMP-8 analysis, P.A. was responsible for the 16S bacterial  
246 analysis, SN was responsible for the plaque imaging, N.M. was responsible for the clinical  
247 study performance and sample collection under the guidance of A.K. All authors contributed  
248 to the drafting or revising the paper and contributed to the intellectual content of the work. All  
249 authors have approved the final version of the manuscript and ensure the integrity of the data  
250 collection and analysis for all aspects of the work.

251 **REFERENCES**


- 252 [1] M.A. Peres, L. Macpherson, R. J. Weyant, B. Daly, R. Venturelli, M. R. Mathur, S.  
253 Listl, R. K. Celeste, C. C. Guarnizo-Herreño, C. Kearns, H. Benzian, P. Allison, R. G.  
254 Watt, *Lancet* 2019, **394**, 249.
- 255 [2] GBD 2017 Disease and Injury Incidence and Prevalence Collaborators, *Lancet* 2018,  
256 **392**, 1789.
- 257 [3] M. Kuboniwa, R. J. Lamont, *Periodontol.* 2000, **52**, 38.
- 258 [4] B. L. Pihlstrom, B. S. Michalowicz, N. W. Johnson, *Lancet* 2005, **366**, 1809.
- 259 [5] C. Dörfer, C. Benz, J. Aida, G. Campard, *Int. Dent. J.* 2017, **67**, 14.
- 260 [6] K. Konopka, T. Goslinski, *J. Dent. Res.* 2007, **86**, 694.
- 261 [7] S. Nikinmaa, H. Alapulli, P. Auvinen, M. Vaara, J. Rantala, E. Kankuri, T. Sorsa, J.  
262 Meurman, T. Pätälä, *PloS one*, 2020, 15, e0232775.
- 263 [8] T. J. Dougherty, C. J. Gomer, B. W. Henderson, G. Jori, D. Kessel, M. Korbelik, J.  
264 Moan, Q. Peng, *J. Natl. Cancer Inst.* 1998, **90**, 889.
- 265 [9] J. T. Alander, I. Kaartinen, A. Laakso, T. Pätälä, T. Spillman, V. V. Tuchin, M.  
266 Venermo, P. Välisuo. *Int. J. Biomed. Imaging* 2012, **2012**, 940585.
- 267 [10] C. Giraudeau, A. Moussaron, A. Stallivieri, S. Mordon, C. Frochot, *Curr. Med. Chem.*  
268 2014, **21**, 1871.
- 269 [11] F. Aytac Bal, I. Ozkocak, B. H. Cadirci, E. Sirin Karaarslan, M. Cakdinleyen, M.  
270 Agaccioglu, *Photodiagnosis Photodyn. Ther.* 2019, **26**, 229.
- 271 [12] C. N. Eroglu, S. Keskin Tunc, R. Erten, A. Usumez, *Photodiagnosis Photodyn. Ther.*  
272 2018, **21**, 416.
- 273 [13] G. Hill, C. Dehn, A. V. Hinze, M. Frentzen, J. Meister, *Photodiagnosis. Photodyn.*  
274 *Ther.* 2019, **26**, 29.
- 275 [14] A. Monzavi, Z. Chinipardaz, M. Mousavi, R. Fekrazad, N. Moslemi, A. Azaripour, O.  
276 Bagherpasand, N. Chiniforush, *Photodiagnosis Photodyn. Ther.* 2016, **14**, 93.
- 277 [15] S. Shingnapurkar, D. Mitra, M. Kadav, R. Shah, S. Rodrigues, S. Prithyani, *Indian J.*  
278 *Dent. Res.* 2016, **27**, 609.
- 279 [16] K. Srikanth, R. V. Chandra, A. A. Reddy, B. H. Reddy, C. Reddy, A. Naveen,  
280 *Quintessence Int.* 2015, **46**, 391.
- 281 [17] A. Tavares, C. M. Carvalho, M. A. Faustino, M. G. Neves, J. P. Tomé, A. C. Tomé, J.  
282 A. Cavaleiro, A. Cunha, N. C. Gomes, E. Alves, A. Almeida, *Mar. Drugs* 2010, **8**, 91.
- 283 [18] World Health Organization. Fact Sheet: Oral health. [https://www.who.int/news-](https://www.who.int/news-room/fact-sheets/detail/oral-health)  
284 [room/fact-sheets/detail/oral-health](https://www.who.int/news-room/fact-sheets/detail/oral-health). 25 March 2020

- 285 [19] R. Hanemaaijer, T. Sorsa, Y. T. Konttinen, Y. Ding, M. Sutinen, H. Visser, V. W. van  
286 Hinsbergh, T. Helaakoski, T. Kainulainen, H. Rönkä, H. Tschesche, T. Salo, *J. Biol.*  
287 *Chem.* 1997, **272**, 31504.
- 288 [20] P. Mäntylä, M. Stenman, D. F. Kinane, S. Tikanoja, H. Luoto, T. Salo, T. Sorsa, *J.*  
289 *Periodontal Res.* 2003, **38**, 436.
- 290 [21] T. Sorsa, U. K. Gursoy, S. Nwhator, M. Hernandez, T. Tervahartiala, J. Leppilahti, M.  
291 Gursoy, E. Könönen, G. Emingil, P. J. Pussinen, P. Mäntylä, *Periodontol.* 2000, **70**,  
292 142.
- 293 [22] T. Sorsa, M. Hernández, J. Leppilahti, S. Munjal, L. Netuschil, P. Mäntylä, *Oral Dis.*  
294 2010, **16**, 39.
- 295 [23] P. A. B. Pereira, V. T. E. Aho, L. Paulin, E. Pekkonen, P. Auvinen, F. Scheperjans,  
296 *Parkinsonism Relat. Disord.* 2017, **38**, 61.
- 297 [24] P. D. Schloss, S. L. Westcott, T. Ryabin, J. R. Hall, M. Hartmann, E. B. Hollister, R. A.  
298 Lesniewski, B. B. Oakley, D. H. Parks, C. J. Robinson, J. W. Sahl, B. Stres, G. G.  
299 Thallinger, D. J. Van Horn, C. F. Weber, *Appl. Environ. Microbiol.* 2009, **75**, 7537.
- 300 [25] M. R. Hamblin, T. Hasan, *Photochem. Photobiol. Sci* 2004, **5**, 436.
- 301 [26] D. Fried, R. E. Glens, J. D. B. Featherstone, W. Seka, *Appl. Opt.* 1995, **34**, 1278.
- 302 [27] C. Chen, C. Hemme, J. Beleno, Z. J. Shi, D. Ning, Y. Qin, Q. Tu, M. Jorgensen, Z. He,  
303 L. Wu, J. Zhou, *ISME J.* 2018, **12**, 1210.
- 304 [28] F. Trindade, F. G. Oppenheim, E. J. Helmerhorst, F. Amado, P. S. Gomes, R. Vitorino,  
305 *Proteomics Clin. Appl.* 2015, **8**, 748.
- 306 [29] T. Takeshita, S. Kageyama, M. Furuta, H. Tsuboi, K. Takeuchi, Y. Shibata, Y.  
307 Shimazaki, S. Akifusa, T. Ninomiya, Y. Kiyohara, Y. Yamashita, *Sci. Rep.* 2016, **6**,  
308 222164.
- 309 [30] C. Y. Tsai, C. Y. Tang, T. S. Tan, K. H. Chen, K. H. Liao, M. L. Liou, *J. Microbiol.*  
310 *Immunol. Infect.* 2018, **51**, 226.
- 311 [31] W. F. Liljemark, C. G. Bloomquist, L. A. Uhl, E. Scheffer, L. Wolff, B. Pihlström, C. L.  
312 Bandt, *Infect. Immun.* 1984, **46**, 778.

## 313 FIGURES AND CAPTIONS




314  
 315 **Figure 1. A.** The small-form-factor LED-based light applicator surface in lollipop form. The  
 316 linear scale is in centimeters **B.** Study workflow. 16S, bacteriome 16S rRNA sequencing;  
 317 CGF cervical gingival fluid; aPTT, antimicrobial photothermal therapy. **C, D.** Selective  
 318 indocyanine green (ICG) localization to the dental plaque. Daylight (**C**) and (**D**) near-infrared  
 319 light images after ICG mouth rinse. Representative images at day 2, when the teeth had been  
 320 without cleaning for a single day. \* premolar one and \*\* premolar two.



321

322 **Figure 2. A,B.** Comparison of dental plaque formation. Panel A shows plaque (area 62.7% of  
 323 total premolar dental area) on the control side in the last imaging session. Premolar one (\*)  
 324 and premolar two (\*). Panel B shows plaque (area 33.8% of total premolar dental area) on the  
 325 treatment side at the same time point. C. Plaque areas at the end of study after four days of  
 326 aPTT application. Paired measurements demonstrated significantly less plaque formation on  
 327 the treated side compared to control side.



328

329 **Figure 3. A.** Matrix metalloproteinase-8 (MMP-8) concentrations at indicated days and sides  
 330 in samples from gingival pockets. aPTT effect on MMP-8 secretion significantly lower on the  
 331 aPTT-treated side than on the control side after the last application of aPTT at end-of-study.  
 332 **B.** Analysis of bacteriome using 16S rRNA sequencing. This figure shows the diversity of  
 333 bacteria within the plaque samples from the treatment and control premolars at the start of the  
 334 treatment at baseline and at the end of the study period. At the end of treatment, a significant  
 335 reduction in the relative proportion of *Streptococcus*, *Actinomyces*, and *Rothia* bacteria  
 336 species was identified, and a relative increase in the *Neisseria*, *Haemophilus*, and *Leptotrichia*  
 337 bacteria species was seen between treated and control side. \*  $p < 0.05$ , \*\*  $p < 0.01$ , \*\*\*  $p < 0.001$